Omeros' narsoplimab pivotal trial data to be shared as an oral presentation at the european hematology association congress

Seattle--(business wire)--omeros corporation (nasdaq: omer) today announced that data on organ function improvement from omeros' pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) will be shared as an oral presentation at the 2021 european hematology association (eha) virtual congress. the presentation, entitled narsoplimab (oms721) treatment contributes to improvements in organ function in adult patients with hi
OMER Ratings Summary
OMER Quant Ranking